Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Forodesine hydrochloride will be administered orally at a dose of 200 mg daily for 7 days each week for 4 weeks (cycle number 1). The drug will be administered once daily one hour prior to or two hours after meals. Patients will be evaluated after 1 full cycle of therapy (28 days).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Ages 18 years and older
Diagnosis of CLL established by peripheral blood and bone marrow examination and using the standard criteria
Patients with Rai stage III or IV, or earlier stage with massive, symptomatic lymphadenopathy requiring therapy
Primary resistance to fludarabine-based therapy (no complete response [CR] or partial response [PR]) or progressive disease within 6 months of response to prior fludarabine containing regimen.
ECOG performance status of 0, 1, 2 or 3
Willing to take adequate contraception (i.e. latex condom, cervical cap, diaphragm, abstinence, etc.) for the entire duration of the study and 3 months after
All investigational treatments should have been discontinued for at least 1 week prior to the initiation of the study drug.
Pregnant or nursing
Unable or unwilling to sign consent
Severe, ongoing co-morbid conditions, which would preclude safe delivery of the investigational therapy
Active serious infections that are not controlled by antibiotics
ECOG performance status 4
Inadequate renal function: creatinine 2.0 or more unless related to the disease
Inadequate liver function: bilirubin 3.0 or more, transaminases 3 x upper limit of normal or more unless related to the disease
Known positive test for HIV
Patients with known hepatitis B and/or hepatitis C active infection